NAD Deficiency in Mice: Niacin Repletion Improved Several Health Measures

On October 12, 2026, NAD.com published a report on a Mayo Clinic study in mice engineered to depend on dietary niacin. The study examined how chronic NAD deficiency affected survival and health, then tested whether niacin repletion could reverse changes associated with that deficiency.

The results linked NAD deficiency to broad health decline

Chronic NAD deficiency in this experimental model was accompanied by increased mortality and a broad deterioration in health. According to the accompanying report, niacin repletion improved frailty and physical performance alongside several metabolic and molecular measurements. The central result is therefore a deficiency-and-recovery finding: removing a nutrient that these mice depended on disrupted multiple aspects of health, while putting it back reversed many measured changes.

This was an animal study in genetically engineered mice.

Dietary niacin controlled the experimental model

The report describes a model built around dependence on dietary niacin. That dependence gave the experiment a clear starting point: researchers could compare mice receiving niacin with mice deprived of it. In this setting, the diet was the condition used to create chronic NAD deficiency. The study therefore centered on the consequences of removing something the animals depended on.

This design connects the dietary change to the reported health changes within a deliberately constructed system. The researchers then used repletion to ask a second question: how much of the resulting decline would respond when niacin was supplied again? Read in that sequence, the study moves from creating a deficiency to testing recovery from it.

Survival tracked the consequences of deprivation

According to NAD.com's account, niacin-deprived mice had increased mortality during roughly six months of observation. All mice receiving a niacin-containing diet survived that observation period. The comparison puts survival alongside the study's other health measurements, making the consequences of deprivation more substantial than a change in a molecular marker alone.

The useful question at this stage is what happened under the experimental conditions. The mortality observation belongs to mice experiencing the induced shortage. It provides the survival component of the reported result, while the rescue phase provides a separate picture of how measured health features responded to repletion.

Repletion improved functional and metabolic measurements

The report describes a rescue group that received niacin after 15 weeks without it. Those animals then underwent six weeks of repletion. This sequence is important because the intervention followed the period of deprivation. The experiment was therefore testing a response to an existing deficiency rather than simply comparing two diets from the beginning.

NAD.com reports improvements in frailty and treadmill performance after repletion. Body weight also improved. These measures bring the result closer to the animal's overall condition and physical function, rather than restricting the analysis to a laboratory readout. For readers interested in healthspan, that functional component is a central part of the study.

The same account reports improvements in blood glucose and bone mass. It also describes reductions in inflammation and oxidative-stress markers, along with senescent-cell markers. Together, these findings show that the response to repletion was observed across several categories of measurement. The reported recovery included physical performance and metabolic features as well as molecular signals.

Each category answers a different question. Treadmill performance concerns how the animals performed in a physical task. Glucose and bone measurements concern other features of their condition. The molecular measurements describe signals associated with the deficiency, giving the experiment several ways to assess what changed after niacin returned to the diet.

That range is useful when reading the result because it keeps the endpoints visible. The study did not report just a single favorable signal. Its reported findings connected the induced shortage with multiple health changes and then followed several of those changes during repletion. The strongest description stays close to those specific observations.

Liver gene measurements showed a large response

The report also describes a substantial change in liver gene measurements after niacin treatment. It states that 3,409 of 3,695 liver genes altered by NAD deficiency were no longer altered after repletion. This finding adds a molecular comparison to the physical and metabolic observations.

The relevant comparison is between the deficiency-associated pattern and the pattern after niacin was supplied again. The reported count shows that many of the gene changes associated with the experimental shortage were no longer present in that comparison. It is another way the rescue phase tracked recovery within the model.

For interpreting the experiment, the gene result is most useful alongside the other endpoints. It shows that the response was not confined to treadmill performance or body weight. The report describes changes at several levels of measurement, from whole-animal performance to liver gene readouts. This makes the deficiency model informative about a broad response to deprivation and repletion.

The model sets clear limits on interpretation

• The deficiency was engineered, not ordinary aging. These mice were made to depend on dietary niacin. Reversing that induced deficiency is not equivalent to reversing the usual course of aging in animals or people. The appropriate scope is a response to a deliberately created shortage, rather than a general claim about human longevity.
• The survival result was limited to the observation period. Increased mortality during deprivation and survival in the niacin-fed group do not establish an extension of total lifespan. The report explicitly says the experiments did not establish lifespan restoration. A recovery in measured health features is a different result from showing a longer life.
• The account does not provide enough detail to quantify survival precisely. It supplies no exact survival percentages or exact group sizes. Median and maximum lifespan are also not given. These gaps prevent a precise assessment of the size of the survival difference from the reported account.
• The liver result was substantial but not complete normalization. The reported gene count concerns the changes associated with deficiency in the liver. It should not be translated into a claim that every liver gene returned to a baseline pattern or that every tissue responded in the same way.
• The molecular endpoints were marker measurements. Reduced oxidative-stress or senescent-cell markers describe what changed in those readouts. They are not interchangeable with demonstrating that all corresponding biological processes were fully resolved. The functional and metabolic findings should therefore retain their own identity rather than being compressed into an all-purpose statement about rejuvenation.

A useful way to read this study is to keep three elements together: the starting condition, the intervention and the measured outcome. Here the starting condition was induced NAD deficiency. The intervention was niacin repletion. The outcomes included survival during observation and several measures of recovery.

For a longevity claim to follow, its evidence needs to match the endpoint being claimed. That is the same interpretive discipline involved in reading biological-age measurements in context and assessing a biomarker's clinical meaning. A striking molecular result is worth attention, but the reader should still ask which organism was studied and which outcome was actually measured.

The practical takeaway is to treat this study as evidence about deficiency and recovery rather than as a supplement recommendation. It offers a focused question for further research on NAD biology. Personal decisions about niacin should be discussed with a qualified health care professional, not inferred from this mouse experiment.

Validation needs studies beyond the deficiency model

The next step is to test NAD-focused interventions in normally aging animals with full-lifespan follow-up before considering well-controlled human studies that measure meaningful health outcomes.

How AgeAmaze helps

A niacin rescue experiment becomes misleading when recovery from an engineered shortage is presented as a human longevity benefit. AgeAmaze helps research-minded readers distinguish animal findings from human evidence through clear explanations of the biology and its uncertainties, keeping promising mouse results in proportion to the questions they actually answer.

Read the research

Sources

1. NAD+ Depletion Shortens Lifespan in Mice—but Restoring ...